Substance P Drives Immune Dysfunction in Dry Eye Disease — Blocking It Restores Balance
Substance P impairs regulatory T cell function in dry eye disease, and blocking its receptor (NK1R) restores immune balance and ameliorates disease severity.
Quick Facts
What This Study Found
Substance P promotes Treg dysfunction in DED, and NK1R antagonist treatment restores Treg function, suppresses Th17 responses, and ameliorates disease severity in mice.
Key Numbers
SP ↑ in DED; SP reduced Treg frequency/function; NK1R antagonist restored Tregs; Th17 suppressed; DED ameliorated
How They Did This
In vitro Treg cultures with substance P and NK1R antagonist, in vivo NK1R antagonist treatment in dry eye disease mouse model, flow cytometry for Treg and Th17 analysis.
Why This Research Matters
Dry eye disease lacks targeted treatments. This study identifies substance P/NK1R as a druggable pathway that corrects the fundamental immune imbalance driving the disease.
The Bigger Picture
This connects neuropeptide signaling to autoimmune-type inflammation in the eye, suggesting NK1R antagonists could be a new treatment class for dry eye and potentially other mucosal surface diseases.
What This Study Doesn't Tell Us
Mouse model of DED. NK1R antagonist effects need validation in human DED. Exact mechanism of SP-mediated Treg suppression not fully elucidated.
Questions This Raises
- ?Would topical NK1R antagonists be effective for dry eye in humans?
- ?Does substance P contribute to Treg dysfunction in other autoimmune conditions?
- ?Could NK1R antagonists be combined with existing dry eye treatments?
Trust & Context
- Key Stat:
- Restored Treg function NK1R antagonist reversed substance P-mediated Treg suppression and ameliorated dry eye disease in mice
- Evidence Grade:
- Animal study with both in vitro mechanistic data and in vivo therapeutic validation. Strong preclinical evidence needing human confirmation.
- Study Age:
- Published in 2020. NK1R antagonists for ocular surface disease continue to be investigated.
- Original Title:
- Restoration of Regulatory T-Cell Function in Dry Eye Disease by Antagonizing Substance P/Neurokinin-1 Receptor.
- Published In:
- The American journal of pathology, 190(9), 1859-1866 (2020)
- Authors:
- Taketani, Yukako, Marmalidou, Anna, Dohlman, Thomas H, Singh, Rohan Bir, Amouzegar, Afsaneh, Chauhan, Sunil K, Chen, Yihe, Dana, Reza
- Database ID:
- RPEP-05158
Evidence Hierarchy
Frequently Asked Questions
What causes dry eye disease?
Dry eye involves an imbalance in the immune system at the eye surface. Regulatory T cells that normally suppress inflammation become dysfunctional, allowing inflammatory Th17 cells to damage the eye. This study shows substance P contributes to this immune imbalance.
How could substance P blockers treat dry eye?
By blocking substance P's receptor (NK1R), researchers restored the function of regulatory T cells that suppress inflammation. In mice, this treatment suppressed the harmful Th17 immune response and significantly improved dry eye symptoms.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05158APA
Taketani, Yukako; Marmalidou, Anna; Dohlman, Thomas H; Singh, Rohan Bir; Amouzegar, Afsaneh; Chauhan, Sunil K; Chen, Yihe; Dana, Reza. (2020). Restoration of Regulatory T-Cell Function in Dry Eye Disease by Antagonizing Substance P/Neurokinin-1 Receptor.. The American journal of pathology, 190(9), 1859-1866. https://doi.org/10.1016/j.ajpath.2020.05.011
MLA
Taketani, Yukako, et al. "Restoration of Regulatory T-Cell Function in Dry Eye Disease by Antagonizing Substance P/Neurokinin-1 Receptor.." The American journal of pathology, 2020. https://doi.org/10.1016/j.ajpath.2020.05.011
RethinkPeptides
RethinkPeptides Research Database. "Restoration of Regulatory T-Cell Function in Dry Eye Disease..." RPEP-05158. Retrieved from https://rethinkpeptides.com/research/taketani-2020-restoration-of-regulatory-tcell
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.